Abionyx Pharma Revenue vs. Gross Profit
| ABNX Stock | EUR 1.22 0.01 0.83% |
For Abionyx Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Abionyx Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Abionyx Pharma SA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Abionyx Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Abionyx Pharma SA over time as well as its relative position and ranking within its peers.
Abionyx |
Abionyx Pharma SA Gross Profit vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Abionyx Pharma's current stock value. Our valuation model uses many indicators to compare Abionyx Pharma value to that of its competitors to determine the firm's financial worth. Abionyx Pharma SA is the top company in revenue category among its peers. It also is number one stock in gross profit category among its peers fabricating about 0.38 of Gross Profit per Revenue. The ratio of Revenue to Gross Profit for Abionyx Pharma SA is roughly 2.61 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Abionyx Pharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Abionyx Pharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Abionyx Revenue vs. Competition
Abionyx Pharma SA is the top company in revenue category among its peers. Market size based on revenue of Biotechnology industry is presently estimated at about 44.05 Million. Abionyx Pharma claims roughly 675,000 in revenue contributing just under 2% to stocks in Biotechnology industry.
Abionyx Gross Profit vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Abionyx Pharma |
| = | 675 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Abionyx Pharma |
| = | 259 K |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Abionyx Gross Profit Comparison
Abionyx Pharma is currently under evaluation in gross profit category among its peers.
Abionyx Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Abionyx Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Abionyx Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Abionyx Pharma's change in net profit over the period of time. It can combine multiple indicators of Abionyx Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein therapies for the treatment of cardiovascular and metabolic diseases. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France. ABIONYX PHARMA is traded on Paris Stock Exchange in France.
Abionyx Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Abionyx Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Abionyx Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Abionyx Pharma's important profitability drivers and their relationship over time.
Use Abionyx Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Abionyx Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Abionyx Pharma will appreciate offsetting losses from the drop in the long position's value.Abionyx Pharma Pair Trading
Abionyx Pharma SA Pair Trading Analysis
The ability to find closely correlated positions to Abionyx Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Abionyx Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Abionyx Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Abionyx Pharma SA to buy it.
The correlation of Abionyx Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Abionyx Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Abionyx Pharma SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Abionyx Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Abionyx Pharma position
In addition to having Abionyx Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Funds Thematic Idea Now
Consumer Funds
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Abionyx Stock
To fully project Abionyx Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Abionyx Pharma SA at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Abionyx Pharma's income statement, its balance sheet, and the statement of cash flows.